Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCD105 vs Components in Moderate-to-Severe Acne
NCT04104685Phase 2Completed
- Sponsor
- Vyne Therapeutics
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FCD105 in acne vulgaris, sponsored by Vyne Therapeutics. Started Sep 2019; status: completed.
02
Drugs
FCD105
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04104685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104685.